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Chronic lymphocytic leukaemia (CLL) cells may be induced to undergo plasmacytoid differentiation in vitro 
in response to 12-O-tetradecanoyl phorbol acetate (TPA). We show here that plasmacytoid differentiation 
and the accompanying accumulation of C/t immunoglobulin mRNA are preceded bya rapid transient in- 
crease in the expression of the proto-oncogenes, c-myc and c-fos. In terminally differentiated cells the level 
of c-fos mRNA returned to the original basal level whilst c-myc expression remained appreciably higher 
than in undifferentiated CLL cells. These data support a possible role for c-fos and c-myc in the programmed 
chain of events that occur during terminal differentiation f B-lymphocytes. 
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1. INTRODUCTION 
B cell chronic lymphocytic leukaemia (CLL) 
represents a monoclonal expansion of immature B- 
lymphocytes that are arrested in their differentia- 
tion. When cultured in vitro in the presence of the 
phorbol ester 12-O-tetradecanoyl phorbol 13- 
acetate (TPA) CLL cells can be induced to undergo 
terminal differentiation towards a plasma cell 
phenotype [1]. After 3 days post-induction, the 
cells display a loss of surface immunoglobulin and 
an increase in intracytoplasmic mmunoglobulin 
and acquire ultrastructural features and phenotype 
of lymphoblasts [1,2]. This plasmacytoid differen- 
tiation thus provides a useful in vitro model in 
which to study mechanisms that co-ordinately 
regulate gene expression in the terminal differen- 
tiation of B-lymphocytes. 
Studies on the expression of the nuclear proto- 
oncogenes, c-myc and c-fos during monocyte/ 
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macrophage differentiation have suggested a func- 
tional role for their gene products in the differen- 
tiation processes in this haemopoietic cell lineage 
[3-7]. Here, we have examined the expression of c- 
myc and c-fos during plasmacytoid differentiation 
of CLL cells and have compared this with the ex- 
pression of immunoglobulin heavy chain (C/z) 
mRNA. Our data reveal a unique pattern of ex- 
pression which supports a role for these nuclear 
proto-oncogenes in the programmed chain of 
events occurring during terminal differentiation of
B-lymphocytes. 
2. MATERIALS AND METHODS 
CLL cells were isolated from the peripheral 
blood of three patients (CLL 1-3) by centrifuga- 
tion on lymphoprep gradients (Nyegaard, Norway) 
and depleted of monocytes by adherence to plastic. 
The level of residual monocytes (determined by 
non-specific esterase staining) represented less than 
1 °70 of the total cell population. For induction of 
plasmacytoid differentiation, cells were cultured in 
RPMI medium supplemented with 10070 foetal calf 
Published by Elsevier Science Publishers B. 1I. ( iomedical Division) 
00145793/87/$3.50 © 1987 Federation ofEuropean Biochemical Societies 127 
Volume 215, number 1 FEBS 
serum and 16 nM TPA [1]. Morphological changes 
were apparent by 24 h and by 48 h most cells had 
acquired plasmacytoid features and became 
positive for intracytoplasmic immunoglobulin 
light chain. 
At various time intervals, CLL cells were 
harvested and the total cellular RNA was extracted 
by the guanidinium isothiocyanate procedure [8]. 
The levels of c-fos and c-myc RNA were deter- 
mined by an RNase protection assay using 32p_ 
labelled RNA probes (spec. act. 5 × 108 cpm/ng) 
generated from pSP64 plasmid constructs [9]. For 
c-fos a BamHI + XmnI  fragment encompassing 
exon I (296 base pairs) and 192 base pairs of exon 
II cloned in pSP64 [10] was used as a template. A
c-myc template was constructed by inserting a 340 
base pair PstI + HindlII fragment encompassing 
200 base pairs of the 3 '-end of c-myc exon II [11] 
and 120 base pairs of intervening sequence into 
pSP64. Synthesis of RNA probes and hybridisa- 
tion with cellular RNA (performed overnight in a 
volume of 30/A in sealed capillaries) were carried 
out as in [10]. After digestion with RNase A 
(40/zg/ml) and RNase Tl (2/~g/ml) hybrids were 
denatured and electrophoresed on 5 % 
polyacrylamide-8 M urea sequencing els followed 
by autoradiography. 
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Immunoglobulin heavy chain mRNA was 
monitored by Northern blotting after elec- 
trophoresis of 5-/~g samples of total cellular RNA 
on a 1% agarose-formamide g l. Hybridisation 
with an oligo-primed 32p-labelled [12] 1.3 kbp 
probe encompassing the C/~ heavy chain locus 
[13] and post-hybridisation washes and 
autoradiography were performed as described 
[14]. 
3. RESULTS 
Expression of the cellular proto-oncogene c-fos 
has not previously been studied in B CLL cells. 
Therefore, we initially examined the steady-state 
levels of c-fos mRNA in resting lymphocytes from 
two different CLL patients by using an RNase pro- 
tection assay [9,10]. Fig. lA shows that a major 
fragment of 296 nucleotides corresponding to 
spliced c-fos exon I [10] was detected at a com- 
parable level in both CLL RNA samples. We have 
also detected similar levels of c-fos in two other 
CLL cases not included in this study (not shown). 
When the assay was performed with RNA from the 
promyelocytic ell line HL60, before and after 
TPA-induced monocyte differentiation, an initial 










M C 0 1 4 24 48 0 1 4 24 48 72 90 
Fig. l. Levels of c-fos mRNA during in vitro differentiation of CLL cells. Various cell RNA samples were annealed 
overnight with c-fos probe, digested with RNase and electrophoresed on 5070 polyacrylamide sequencing els. 
Autoradiographs after a 4 day exposure are shown. (A) M, marker; C, control, tRNA (10/~g). la,l b, lc: 1, 4 and 20/~g 
RNA, respectively, from CLL 1. 2:4/tg RNA from CLL 2. HL60 RNA (4/~g) at time 0, 40 min and 48 h (terminally 
differentiated) post-TPA treatment. (B) Time course RNA samples (4 ~ag) following TPA treatment of CLL 2 cells. M, 
marker; C, control, tRNA (10/~g). (C) Time course RNA samples following TPA treatment of CLL 3. Numbers indicate 
time (in h). B and C were performed in parallel and are taken from the same gel. 
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(fig.lA). In terminally differentiated HL60 cells 
(48 h) the level of c-fos RNA was reduced to a
value still manifold higher than that in uninduced 
HL60 cells, consistent with previous work [6]. The 
level of c-fos RNA in resting CLL cells appeared to 
be comparable to that in terminally differentiated 
HL60 cells (fig. 1A). 
Fig. 1B shows an analysis of c-fos mRNA during 
a time course of TPA-induced plasmacytoid if- 
ferentiation of CLL 2 cells. By 1 h post-induction 
the c-fos level was elevated approx. 10-fold. This 
was sustained at 4 h but by 24 h c-fos mRNA was 
reduced to a level comparable to that in resting 
CLL cells. At 48 h post-induction when most cells 
were plasmocytoid, no further change in c-fos 
RNA was seen. Fig. 1C shows a similar analysis for 
CLL 3 cells where a similar rapid, transient induc- 
tion of c-fos was again seen. However, in this case 
c-fos RNA did not completely return to basal levels 
at 24 h. By 48 h c-fos did return to basal evels 
where it remained relatively constant up to 90 h 
post-induction. Since the experiments in fig.lB,C 
were performed in parallel, we attribute this minor 
difference in kinetics of disappearance of c-fos 
RNA to differences between cells from CLL 2 and 
3. 
The time course RNA samples from fig.lB,C 
were next examined for expression of the proto- 
oncogene c-myc. We chose an exon II probe in 
these studies to measure functional c-myc RNA 
(exon I is non-coding), since elongation of c-myc 
transcription may be blocked between exon I and 
intron I [15] although we have obtained identical 
data in initial experiments using an exon I probe 
(not shown). In RNA from resting CLL 2 cells c- 
myc transcripts were not detectable (time 0, 
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Fig.2. Levels of c-myc RNA during in vitro differentiation of CLL cells. Cell RNA samples (4/zg) from CLL 2 (A) and 
CLL 3 (B) or from uninduced HL60 cells (HL) were annealed overnight with c-myc probe then digested with RNase 
and electrophoresed on a 5°70 polyacrylamide s quencing gel. A and B are taken from the same gel. RNA samples and 
time points are exactly as described in fig.lB,C. 
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fig.2A) in agreement with earlier reports showing 
extremely low expression of this proto-oncogene in 
CLL [16]. At 1 h post-induction a burst in c-myc 
expression was seen in CLL 2 (fig.lA) which 
paralleled that of c-fos. The largest protected c- 
rnyc fragment was about 200 nucleotides long 
(marked with an arrow) consistent with the length 
of exon II sequences in the probe. However, in this 
and all other assays of c-myc RNA, a number of 
faster migrating fragments were reproducibly seen 
(fig.2) which could not be eliminated by modifying 
either the hybridisation or RNase digestion condi- 
tions in this assay. Similar spurious bands have 
been observed by other workers using RNase pro- 
tection assays [17]. Although the origin of these 
fragments is not entirely clear they are present in 
roughly constant proportions in all samples ex- 
amined and do not effect the quantitation of 
mRNA. In fig.2A we estimate the level of c-myc 
RNA in CLL2 at 1 h to be about one-fifth of that 
in promyelocytic HL60 cells which contain an 
amplified c-myc locus [18]. This level of c-myc 
RNA was sustained at 4 h but in contrast o c-fos 
the level was reduced only about 3-4-fold at 24 
and 48 h post-induction and is thus appreciably 
higher than in resting CLL cells. An essentially 
similar result was obtained with RNA from CLL 3 
cells (fig.2B) although as with c-los there were 
minor differences in kinetics compared with CLL 
2. Interestingly, c-myc RNA was noticeably lower 
at 1 h than at 4 h in CLL 3 (fig.2B) indicating that 
induction of c-los probably precedes that of c-myc 
(cf. figs 1C,2B). In terminally differentiated CLL 
3 cells c-myc RNA again remained higher than in 
resting CLL cells except for a small diminution at 
90 h at which time cell viability is known to be lost. 
Previously it has been shown that plasmacytoid 
differentiation of CLL cells is accompanied by a 
small increase in immunoglobulin heavy chain 
mRNA and a minor change in splicing pattern 
from the 2.7 kb mRNA (encoding membrane) to 
the 2.4 kb species (encoding secreted im- 
munoglobulin) [19]. In order to compare the 
kinetics of this immunoglobulin mRNA accumula- 
tion with the changes in c-fos and c-myc expression 
a Northern blot analysis of time course RNA 
samples from CLL 3 was performed as shown in 
fig.3. Very little increase in immunoglobulin 
mRNA was seen over the first few hours post- 
induction. At 48 h there was a discernable increase 
Fig.3. Levels of immunoglobulin heavy chain mRNA 
during in vitro differentiation of CLL cells. Northern 
blot analysis of RNA samples at times indicated (in h) is 
shown after hybridisation with immunoglobulin C/z gene 
probe. An autoradiograph is shown after a 4 day 
exposure. Sizes are given in kilobases. The signal 
obtained at 24 h appears lightly under-represented due 
to degradation which was apparent on the ethidium 
bromide-stained gel. 
and at 72 h (essentially complete plasmacytoid dif- 
ferentiation) the level of immunoglobulin mRNA 
was about 2-3-fold higher than in resting CLL 
cells. This increase in accumulation of im- 
munoglobulin RNA is comparable to that reported 
in [19] although we were unable to detect he minor 
change in relative abundance of mRNAs encoding 
membrane-bound and secreted immunoglobulin 
due to slight degradation of the RNA. Thus, in 
contrast o the rapid transient changes in c-fos and 
c-myc expression, the less dramatic hange in im- 
munoglobulin gene expression appears much later 
on in the plasmacytoid developmental programme. 
4. DISCUSSION 
In this report we have shown that TPA-induced 
plasmacytoid ifferentiation of CLL cells and the 
accompanying accumulation of immunoglobulin 
mRNA are preceded by a rapid, transient increase 
in expression of c-fos and c-myc. This pattern of 
oncogene xpression has been observed in several 
cell types that are induced by a variety of agents to 
undergo differentiation or cell division [3-7,171 
although this is the first report to our knowledge of 
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studies using a lymphocyte differentiation model. 
The functional role of the c-fos and c-myc gene 
products is currently highly speculative. The ability 
of these genes to disrupt cellular processes in 
tumourigenesis together with their afore- 
mentioned expression characteristics had led to the 
suggestion that at least one role may be to mediate 
pre-programmed nuclear functions in response to 
transduction of extracellular signals [7]. In the 
plasmacytoid differentiation of CLL cells the 
membrane receptor for TPA, protein kinase C, has 
previously been shown to be rapidly down- 
regulated (within minutes) in response to phorbol 
ester [20]. Thus, the kinetics of c-fos and c-myc ex- 
pression which occurs over the first few hours but 
before onset of cellular differentiation changes 
would clearly be consistent with such a role. 
The pattern of proto-oncogene expression dur- 
ing plasmacytoid differentiation contrasts marked- 
ly with that seen in monocyte/macrophage 
differentiation where there is a net increase in c-fos 
whilst c-myc is reduced in terminally differentiated 
cells [3-7]. In chemically induced terminal dif- 
ferentiation of mouse erythroleukaemia cells, c- 
myc shows an initial rapid decline followed by 
restoration to pretreatment levels after which c- 
myc RNA declines again [21]. It has been sug- 
gested that induction of differentiation leads to a 
change in the cell cycle regulation of c-myc expres- 
sion [21]. Such a mechanism could account for the 
pattern of expression of this gene in plasmacytoid 
differentiation where the CLL cells traverse from 
Go to Gj but cannot proceed to S phase (CLL cells 
are recalcitrant to induction of cell division and 
very little DNA synthesis occurs). In terminally 
differentiated macrophages the elevated expression 
of c-fos (also seen in normal marrow 
macrophages) has been interpreted as supporting a
specific role of the c-fos gene product in terminally 
differentiated cells of this lineage [3,7]. The 
relatively high c-fos expression observed in resting 
CLL cells may reflect a similar functional role. The 
lack of net change on terminal differentiation 
would argue that CLL cells are blocked at a 
relatively late stage in B-lymphocyte maturation. 
ACKNOWLEDGEMENTS 
This work was supported in part by the Medical 
Research Council of Great Britain. We thank Pro- 
LETTERS May 1987 
fessor A.V. Hoffbrand for support and en- 
couragement. 
REFERENCES 
[1] Totterman, T.H., Nilsson, K. and Sundstrom, C. 
(1980) Nature 228, 176-178. 
[2] Gordon, J., Mellstedt, H., Aman, P., Biberfield, 
P. and Kline, G. (1984) J. Immunol. 132,541-547. 
[3] Muller, R., Muller, D. and Guilbert, L. (1984) 
EMBO J. 3, 1887-1890. 
[4] Muller, R., Curran, T., Muller, D. and Guiibert, L. 
(1985) Nature 314, 546-548. 
[5] Gonda, T.J. and Metcalf, D. (1984) Nature 310, 
249-251. 
[6] Mitchell, R.B., Zokas, L., Schreiber, R.D. and 
Verma, I.M. (1985) Cell 40, 209-217. 
[7] Muller, R. (1986) Biochim. Biophys. Acta 823, 
207-255. 
[8] Maniatis, T., Fritch, E.F. and Sandbrook, J. 
(1982) in: Molecular Cloning, A Laboratory 
Manual, pp.188-196, Cold Spring Harbour, New 
York. 
[9] Melton, D.A., Krieg, P.A., Rebagliati, M.R., 
Maniatis, T., Zinn, K. and Green, M.R. (1984) 
Nucleic Acids Res. 12, 7034-7056. 
[10] Treisman, R. (1985) Cell 42, 889-902. 
[11] Alitalo, K., Schwab, M., Linn, C., Varmus, H.E. 
and Bishop, J.M. (1983) Proc. Natl. Acad. Sci. 
USA 80, 1207-1211. 
[12] Feinberg, A.P. and Vogelstein, B. (1983) Anal. 
Biochem. 132, 6-13. 
[13] Ravetch, J.V., Siebenlist, U., Korsmeyer, S., 
Waldman, T. and Leder, P. (1981) Cell 27, 
583-591. 
[14] Carter, A.T., Norton, J.D. and Avery, R.]. (1983) 
Nucleic Acids Res. 11, 6243-6354. 
[15] Bently, D.L. and Groudine, M. (1986) Nature 321, 
702-706. 
[16] Birnie, G.K., Varnock, A.M., Burns, J.H. and 
Clark, P. (1986) Leuk. Res. 10, 515-526. 
[17] Kruijer, W., Cooper, J.A., Hunter, T. and Verma, 
I.M. (1984) Nature 312, 711-716. 
[18] Dalla-Favera, R., Wongstaal, F. and Gallo, R.C. 
(1982) Nature 299, 61-63. 
[19] Cossman, J., Neckers, L.M., Braziel, R.M., 
Trepel, J.B., Korsmeyer, S.J. and Bakhshi, A. 
(1983) J. Clin. Invest. 73, 587-592. 
[20] Wickremasinghe, R.G., Piga, A., Campana, D., 
Yaxley, J.C. and Hoffbrand, A.V. (1985) FEBS 
Lett. 190, 50-54. 
[21] Lackman, H.M., Hatton, K.S., Skoultchi, A.I. 
and Schildkraut, C.L. (1985) Proc. Natl. Acad. Sci. 
USA 82, 5323-5327. 
131 
